 |
Assessment of two therapeutic categories
and sales projections of target's current and pipeline products in these categories |
|
Opportunities and obstacles in co-promoting
a TNF inhibitor with a biotech company |
|
Opportunities and obstacles in exercising
first refusal to develop specified compounds in another company's dermatology pipeline |
|
|
